Podcast: Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer

This case-based podcast presented by i3 Health brings together two leading experts, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, who will examine recent clinical advances and new opportunities in the management of SCLC and discuss key clinical questions engendered by recent advances in treatment and the need for individualized care. Start the activity now.

Statement of Need

An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 14% of cases are classified as small cell lung cancer (SCLC). While SCLC is usually treated with systemic therapy with or without radiation, the 5-year relative survival rate is a dismal 7%, indicating a need for continued research on more effective approaches to tumor control (ACS, 2022). To improve outcomes for patients with SCLC, remaining up to date with the latest clinical data in systemic therapy and radiotherapy is key. In this Video Viewpoint Strategy Session, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, will examine recent clinical advances and new opportunities in the management of SCLC, and discuss key clinical questions engendered by recent advances in treatment and the need for individualized care.

Target Audience

Medical oncologists, surgical oncologists, radiation oncologists, nurse practitioners, physician assistants, pharmacists, oncology nurses, and other health care professionals involved in the treatment of patients with small cell lung cancer (SCLC)

Learning Objectives

-Assess patient-, tumor-, and treatment-related factors that can inform individualized management plans in SCLC
-Appraise recent clinical trial data on the safety and efficacy of novel therapies for metastatic SCLC
-Evaluate strategies to enhance the safety and tolerability of treatment for SCLC